Advances in PD-1/PD-L1 inhibitor combinations with standard therapies for hematological malignancies
Year: 2025
Type: article
Abstract: Hematological malignancies clinically encompass common subtypes including leukemia, lymphoma, and multiple myeloma, and their overall incidence has shown an increasing trend in recent years. As a type of immune checkpoint inhibitor (ICI), programmed death protein-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors can prevent the immune escape of tumor cells and reactivate the body’s anti-tumor immune response. However, single-agent use is prone to issues such as drug resistance and immune-related adverse events. Therefore, PD-1/PD-L1 inhibitors combined with other therapeutic approaches have shown potential therapeutic value in preclinical and clinical settings. This article summarizes the current ICI combination therapies, providing a reference for the treatment of hematological malignancies.
Source: Academia oncology.
Authors: Yaoxuan Zeng, Guancheng He, Zechao Zhang, Min Zhu
Institution: Guangxi University of Chinese Medicine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7117272304